All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Reboxetine
Therapeutic Area: Sleep Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Axsome Therapeutics
Deal Size: $331.0 million Upfront Cash: $3.0 million
Deal Type: Licensing Agreement January 13, 2020
Details:
Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy which expands Axsome’s pipeline with new Phase 3-stage esreboxetine product candidate for fibromyalgia
Transforming oral delivery challenges into proprietary product solutions.
Lead Product(s): Mazindol
Therapeutic Area: Sleep Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: NLS Pharmaceutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 13, 2020
Details:
NLS Pharmaceutics entered a collaboration to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy and ADHD utilizing Adare’s proprietary modified release technologies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lemborexant
Therapeutic Area: Sleep Product Name: Dayvigo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2021
Details:
DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythm.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Sleep Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Centessa Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger February 16, 2021
Details:
Orexia Therapeutics has been merged into Centessa. Orexia is developing oral and intranasal orexin receptor agonists using structure-based drug design approaches.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ramelteon
Therapeutic Area: Sleep Product Name: Rozerem
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2020
Details:
Upsher-Smith’s product is AB-rated to the branded product, ROZEREM® (ramelteon) tablets.* Ramelteon tablets are indicated for the treatment of insomnia characterized by difficulty with sleep onset.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aroxybutynin,Atomoxetine Hydrochloride
Therapeutic Area: Sleep Product Name: AD109
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2020
Details:
First patient has been dosed in first Phase 2 clinical trial evaluating AD109, the company’s first-in-class, oral pharmaceutical under development for the treatment of OSA.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pitolisant
Therapeutic Area: Sleep Product Name: Wakix
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Citrine Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 28, 2020
Details:
The partnership provides Citrine with exclusive rights to develop, register, market, and manufacture Wakix® (pitolisant) in China for the treatment of narcolepsy and obstructive sleep apnea.